Previous 10 | Next 10 |
GERMANTOWN, Md., April 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs...
GERMANTOWN, Md., April 27, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (C...
Orgenesis to Acquire Tamir Biotechnology's Assets for $19 Million Orgenesis Inc. ( ORGS ) reported that it has signed a deal with Tamir Biotechnology Inc., under which the former will acquire the assets of the latter, including its broad spectrum antiviral platform ranpirnase. The deal is ca...
Orgenesis (NASDAQ: ORGS ) has entered into an agreement to acquire the assets of Tamir Biotechnology, including ranpirnase, a broad spectrum anti-viral platform, for total stock and cash consideration of ~$19M. More news on: Orgenesis Inc., Healthcare stocks news, Stocks on the move...
GERMANTOWN, Md., April 13, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gen...
JV to utilize RevaTis’s patented technique to obtain mdMSCs through a minimally invasive muscle biopsy and leverage mdMSC manufacturing capability Plan to leverage Orgenesis’s autologous Cell and Gene Therapy (CGT) Biotech Platform to develop novel therapies and advance ...
GERMANTOWN, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gen...
GERMANTOWN, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gen...
Orgenesis (NASDAQ: ORGS ): FY GAAP EPS of $1.77. Revenue of $33.3M (+78.1% Y/Y) Press Release More news on: Orgenesis Inc., Earnings news and commentary, Healthcare stocks news, ,
Reports 78% increase in revenue and 92% increase in gross profit for fiscal 2019 Generated over $3.1 million in sales through POCare platform Rapidly expanding POCare platform through new collaborations GERMANTOWN, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NA...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 2.7% to $127.255 on volume of 88,797,787 shares Ascent Solar Technologies Inc (ASTI) rose 9.6% to $0.1183 on volume of 88,651,038 shares Crown Electrokinetics Corp. (CRKN) fell 19.0% to $0.040499 on volu...